1 Min Read
June 26 (Reuters) - Lipocine Inc
* Lipocine Inc - Announces submission of special protocol assessment request to FDA on LPCN 1107, an oral alternative for prevention of preterm birth Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.